Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 31 May 2009, doi:10.1136/bmj.b2084
Cite this as: BMJ 2009;338:b2084
May reduce mortality, but longer term results are awaited
| The first 150 words of the full text of this article appear below. |
Evidence supporting colorectal screening, aside from randomised trials of faecal occult blood testing, comes mainly from observational studies. In the linked paper (doi:10.1136/bmj.b1846) interim results of the Norwegian Colorectal Cancer Prevention (NORCCAP) trial are presented.1 NORCCAP is one of three ongoing trials of once only screening sigmoidoscopy.1 2 3 The findings suggest that the intervention may be effective in reducing mortality from colorectal cancer.
The NORCCAP trial randomised 55 736 people aged 55-64 years to usual care or to once only flexible sigmoidoscopy with or without a single round of immunochemical faecal occult blood testing. The primary outcome for this first report is 7 year cumulative incidence of colorectal cancer (anywhere in the colon); the secondary outcome is 6 year mortality from colorectal cancer. Colonoscopy, which was done in 21% of patients screened, was recommended for people with a positive screening result, defined as any polyp 10 mm or larger
Thomas F Imperiale, professor of medicine, research scientist1,2
1 Indiana University Medical Center, Indianapolis, IN, USA, 2 Regenstrief Institute, Indianapolis, IN 46202-5121, USA
timperia@iupui.edu